$RARE 8-K SEC Filings

On October 19, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) and Baylor Research Institute (“BRI”) entered into a settlement agreement with Navinta LLC (“Navinta”) resolving patent litigation related to patents covering the Compan...

On October 8, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) entered into an asset purchase agreement (the “PRV Asset Purchase Agreement”), pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority Review Vouch...

On October 6, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) entered into an asset purchase agreement (the “PRV Asset Purchase Agreement”), pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority Review Vouch...

On September 17, 2026, Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) announced that the U.S. Food and Drug Administration (the “FDA”) granted standard full approval of FAYUVI™ (rebisufligene etisparvovec-hopf), also know...